Standard BioTools, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US34385P1084
USD
1.44
0.02 (1.41%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Standard BioTools, Inc. stock-summary
stock-summary
Standard BioTools, Inc.
Pharmaceuticals & Biotechnology
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company's core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.
Company Coordinates stock-summary
Company Details
7000 Shoreline Ct Ste 100 , SOUTH SAN FRANCISCO CA : 94080-7603
stock-summary
Tel: 1 650 2666000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 32 Schemes (15.22%)

Foreign Institutions

Held by 79 Foreign Institutions (12.03%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Carlos Paya
Independent Chairman of the Board
Mr. Stephen Linthwaite
President, Chief Executive Officer, Director
Ms. Ana Stankovic
Director
Mr. Nicolas Barthelemy
Independent Director
Mr. Gerhard Burbach
Independent Director
Ms. Laura Clague
Independent Director
Dr. Bill Colston
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
22 Million
(Quarterly Results - Jun 2025)
Net Profit:
-18 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 520 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.55

stock-summary
Return on Equity

-21.09%

stock-summary
Price to Book

1.22